ICON Public Limited Company (ICLR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 210.86 |
| Open | 212.54 |
| Bid | 187.00 x 800 |
| Ask | 213.31 x 800 |
| Day's Range | 210.80 - 214.34 |
| 52 Week Range | 171.43 - 263.62 |
| Volume | |
| Avg. Volume | 516,280 |
| Market Cap | 17.455B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 34.23 |
| EPS (TTM) | 6.24 |
| Earnings Date | Apr 26, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 262.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ICLR
Related Research
- ICON plcAnalyst Report: ICON Public Limited CompanyIcon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.RatingFair ValueEconomic Moatlast monthMorningstar
- Simply Wall St.
ICON's (NASDAQ:ICLR) investors will be pleased with their notable 84% return over the last five years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
- Business Wire
ICON plc Schedules First Quarter 2023 Earnings Conference Call
DUBLIN, March 29, 2023--ICON plc Schedules First Quarter 2023 Earnings Conference Call
- Motley Fool
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.
